CALLABLE KICK-IN GOAL LINKED TO WORST OF - ROCHE GS/ALCON AG/NOVARTIS N Share Price

Certificat

KNFSDU

CH1234249527

Market Closed - Swiss Exchange 16:20:00 17/05/2024 BST
97.8 CHF +0.15% Intraday chart for CALLABLE KICK-IN GOAL LINKED TO WORST OF - ROCHE GS/ALCON AG/NOVARTIS N
Current month+1.29%
1 month+1.56%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
17/05/24 97.8 +0.15%
16/05/24 97.65 +0.46%
15/05/24 97.2 +0.10%
13/05/24 97.1 +0.47%
10/05/24 96.65 +0.21%

Delayed Quote Swiss Exchange

Last update May 17, 2024 at 04:20 pm

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
KNFSDU
ISINCH1234249527
Date issued 14/12/2022
Strike 307.6 CHF
Maturity 16/12/2024 (213 Days)
Parity 0.31 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 100.7 CHF
Lowest since issue 93.8 CHF
Spread 10 CHF
Spread %1.01%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus
  1. Stock Market
  2. Certificates
  3. KNFSDU Certificat